These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 26644410

  • 1. Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
    Raje N, Vescio R, Montgomery CW, Badros A, Munshi N, Orlowski R, Hadala JT, Warsi G, Argonza-Aviles E, Ericson SG, Anderson KC.
    Clin Cancer Res; 2016 Mar 15; 22(6):1378-84. PubMed ID: 26644410
    [Abstract] [Full Text] [Related]

  • 2. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Boyd KD, Osborne WL, Cook G, Child JA.
    Br J Haematol; 2014 Jul 15; 166(1):109-17. PubMed ID: 24673708
    [Abstract] [Full Text] [Related]

  • 3. Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors.
    Van den Wyngaert T, Delforge M, Doyen C, Duck L, Wouters K, Delabaye I, Wouters C, Wildiers H.
    Support Care Cancer; 2013 Dec 15; 21(12):3483-90. PubMed ID: 23955094
    [Abstract] [Full Text] [Related]

  • 4. Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.
    Henk HJ, Teitelbaum A, Perez JR, Kaura S.
    Am J Hematol; 2012 May 15; 87(5):490-5. PubMed ID: 22454220
    [Abstract] [Full Text] [Related]

  • 5. Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
    Patel CG, Yee AJ, Scullen TA, Nemani N, Santo L, Richardson PG, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Raje NS.
    Clin Cancer Res; 2014 Aug 01; 20(15):3955-61. PubMed ID: 24958808
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
    Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE.
    J Thorac Oncol; 2008 Mar 01; 3(3):228-36. PubMed ID: 18317064
    [Abstract] [Full Text] [Related]

  • 8. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
    Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL.
    JAMA; 2017 Jan 03; 317(1):48-58. PubMed ID: 28030702
    [Abstract] [Full Text] [Related]

  • 9. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 03; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 10. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J.
    Cancer Invest; 2002 Jul 03; 20 Suppl 2():45-54. PubMed ID: 12442349
    [Abstract] [Full Text] [Related]

  • 11. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
    Raje N, Roodman GD, Willenbacher W, Shimizu K, García-Sanz R, Terpos E, Kennedy L, Sabatelli L, Intorcia M, Hechmati G.
    J Med Econ; 2018 May 03; 21(5):525-536. PubMed ID: 29480139
    [Abstract] [Full Text] [Related]

  • 12. Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.
    Søe K, Delaissé JM, Jakobsen EH, Hansen CT, Plesner T.
    Acta Oncol; 2014 Apr 03; 53(4):547-56. PubMed ID: 24164102
    [Abstract] [Full Text] [Related]

  • 13. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.
    Rajpar S, Massard C, Laplanche A, Tournay E, Gross-Goupil M, Loriot Y, Di Palma M, Bossi A, Escudier B, Chauchereau A, Fizazi K.
    Ann Oncol; 2010 Sep 03; 21(9):1864-1869. PubMed ID: 20181574
    [Abstract] [Full Text] [Related]

  • 14. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
    Broom RJ, Hinder V, Sharples K, Proctor J, Duffey S, Pollard S, Fong PC, Forgeson G, Harris DL, Jameson MB, O'Donnell A, North RT, Deva S, Hanning FJ, Grey A, Findlay MP.
    Clin Genitourin Cancer; 2015 Feb 03; 13(1):50-8. PubMed ID: 25163397
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
    Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S.
    J Clin Oncol; 2009 Apr 01; 27(10):1564-71. PubMed ID: 19237632
    [Abstract] [Full Text] [Related]

  • 17. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
    Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, Andriani A, D'Arena G, Balleari E, Pietrantuono G, Boccadoro M, Palumbo A, GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network.
    Cancer; 2008 Oct 01; 113(7):1588-95. PubMed ID: 18683218
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
    Hu XY, Zou QF, Jin C, Li WD, Chen WS, Ma L.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun 01; 30(6):1343-6. PubMed ID: 20584674
    [Abstract] [Full Text] [Related]

  • 19. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
    Lipton A, Cook RJ, Major P, Smith MR, Coleman RE.
    Oncologist; 2007 Sep 01; 12(9):1035-43. PubMed ID: 17914073
    [Abstract] [Full Text] [Related]

  • 20. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.
    Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A.
    JAMA Oncol; 2017 Jul 01; 3(7):906-912. PubMed ID: 28125763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.